Portal Vein Embolization (PVE) Versus PVE with Haematopoietic Stem Cell Application in Patients with Primarily Non-resectable Colorectal Liver Metastases
Jazyk angličtina Země Řecko Médium print
Typ dokumentu srovnávací studie, časopisecké články
PubMed
30194213
DOI
10.21873/anticanres.12888
PII: 38/9/5531
Knihovny.cz E-zdroje
- Klíčová slova
- Colorectal liver metastases, future liver remnant volume, portal vein embolization, stem cells,
- MeSH
- časové faktory MeSH
- Kaplanův-Meierův odhad MeSH
- kolorektální nádory mortalita patologie MeSH
- kombinovaná terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory jater mortalita sekundární terapie MeSH
- přežití bez známek nemoci MeSH
- regenerace jater * MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- senioři MeSH
- terapeutická embolizace škodlivé účinky metody MeSH
- transplantace hematopoetických kmenových buněk * škodlivé účinky mortalita MeSH
- transplantace mezenchymálních kmenových buněk * škodlivé účinky mortalita MeSH
- vena portae * MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
BACKGROUND: Portal vein embolization (PVE) and PVE with autologous mesenchymal stem cell application (PVE-MSC) increases future liver remnant volume (FLRV). The aim of this study was to compare both methods from the aspect of FLRV growth, progression of colorectal liver metastases (CLM), CLM resectability and long-term results. PATIENTS AND METHODS: Fifty-five patients with CLM and insufficient FLRV were included in the study. FLVR growth and CLM volume were evaluated using computed tomography. Liver resection was performed in patients with FLVR >30% of total liver volume. RESULTS: In the PVE (N=27) group, FLRV growth was observed in 23 patients (85.2%) and in 100% of patients in the PVE-MSC (N=28) group (p<0.05). The rapidity of FLRV and CLM growth did not differ between groups. R0 resection was performed in 14 (51.8%) and 24 (85.7%) patients from the PVE and PVE-MSC (p<0.02) groups, respectively. The 3-year overall and progression-free survival rates were 85.75% and 9.3% in the PVE group and 68.7% and 17.1% in the PVE-MSC group, respectively (p<0.67 and p<0.84, respectively). CONCLUSION: PVE-MSC allows for more effective growth of FLRV and resectability of CLM compared to PVE. The two methods do not differ in their long-term results.
Department of Hemato oncology University Hospital Faculty of Medicine Pilsen Czech Republic
Department of Immunochemistry University Hospital Faculty of Medicine Pilsen Czech Republic
Department of Radiology University Hospital Faculty of Medicine Pilsen Czech Republic
Department of Surgery University Hospital Faculty of Medicine Pilsen Czech Republic
Citace poskytuje Crossref.org
